学会発表（国際）
Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy : First safety analysis of CREATE-X (JBCRG-04).
Ohtani S, Masuda N, Im Y-H, Im S-A, Park B-W, Kim S-B, Yanagita Y, Takao S, Ohno S, Aogi K, Iwata H, Yoshidome K, Nishimura R, Lee E-S, Yokota I, Ohashi Y, Lee S-J, Toi M. Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy : First safety analysis of CREATE-X (JBCRG-04). 2013 CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 12, 2013. Session # P3-12-03.